▶ GH FRAGMENT (LIPOLYTIC) · SUBTOPIC · SAFETY PROFILE
GH FRAGMENT (LIPOLYTIC) Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of GH FRAGMENT (LIPOLYTIC).
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of GH FRAGMENT (LIPOLYTIC). Severity, frequency, and attribution depend on the source publication.
- Generally well-tolerated in trials at the doses tested
- Injection-site reactions
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for GH FRAGMENT (LIPOLYTIC).
- Not characterized in Phase 3
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for GH FRAGMENT (LIPOLYTIC) in the published record:
- Pregnancy/lactation (unstudied)
FDA REGULATORY STATUS
Not FDA-approved as a drug.
WADA REGULATORY STATUS
Growth hormone fragments prohibited at all times under S2 on the WADA Prohibited List.
OTHER JURISDICTIONS
Australia · Australian TGA placed AOD-9604 on Schedule 4 (prescription medicine) in 2020.
SAFETY Q+A FROM LITERATURE
▶ Is AOD-9604 FDA-approved?
No. AOD-9604 is not FDA-approved as a drug. It had limited food-supplement GRAS history in some jurisdictions but Australia's TGA placed it on Schedule 4 (prescription) in 2020.
▶ Is AOD-9604 banned in sports?
Yes, in effect. Growth hormone fragments are prohibited at all times under S2 (peptide hormones, growth factors, related substances) on the WADA Prohibited List.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Heffernan M, et al.. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology 2001. PMID 11713213. link
- Ng FM, et al.. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res 2000. PMID 11146368. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19